Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

Background Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatiti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology international 2021-04, Vol.15 (2), p.510-519
Hauptverfasser: Biewenga, Maaike, van der Kooij, Monique K., Wouters, Michel W. J. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan Willem B., Boers-Sonderen, Marye J., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Haanen, John B. A. G., van der Eertwegh, Alfons J. M., van Hoek, Bart, Kapiteijn, Ellen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatitis is related to liver metastasis and outcome in a real-world nationwide cohort. Methods Data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR) was used to analyze incidence, risk factors of checkpoint inhibitor-induced grade 3–4 hepatitis and outcome. Results 2561 advanced cutaneous melanoma patients received 3111 treatments with checkpoint inhibitors between May 2012 and January 2019. Severe hepatitis occurred in 30/1620 (1.8%) patients treated with PD-1 inhibitors, in 29/1105 (2.6%) patients treated with ipilimumab and in 80/386 (20.7%) patients treated with combination therapy. Patients with hepatitis had a similar prevalence of liver metastasis compared to patients without hepatitis (32% vs. 27%; p  = 0.58 for PD-1 inhibitors; 42% vs. 29%; p  = 0.16 for ipilimumab; 38% vs. 43%; p  = 0.50 for combination therapy). There was no difference in median progression free and overall survival between patients with and without hepatitis (6.0 months vs. 5.4 months progression-free survival; p  = 0.61; 17.0 vs. 16.2 months overall survival; p  = 0.44). Conclusion Incidence of hepatitis in a real-world cohort is 1.8% for PD-1 inhibitor, 2.6% for ipilimumab and 20.7% for combination therapy. Checkpoint inhibitor-induced hepatitis had no relation with liver metastasis and had no negative effect on the outcome.
ISSN:1936-0533
1936-0541
DOI:10.1007/s12072-021-10151-4